IP Library Granted Patent US 11,607,419
Granted Patent B2
US 11,607,419 · App. 16/620,237 · Granted Mar 21, 2023

Inhibitors of RAC1 and uses thereof for inducing bronchodilatation

Inventors: Vincent Sauzeau (Bouguenais, FR); Gervaise Loirand (Thouare-sur-Loire, FR); Jacques Lebreton (Nantes, FR); Arnaud Tessier (Orvault, FR); Agnes Quemenier (Nantes, FR)
Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE DE NANTES; CHU NANTES
A61K31/63A61P11/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,607,419
App. No.
16/620,237
Granted
Mar 21, 2023
Kind
B2
Abstract

The present invention concerns a compound having the following formula (I): wherein: —A is in particular —N(R′ a )—C(═O)—R, R′ a being H or a (C 1 -C 6 )alkyl group, and R being preferably a group having the following formula (II): —X is in particular chosen from the group consisting of: —SO 2 —N(R′ b )—, R′ b being H or a (C 1 -C 6 )alkyl group, —N(R″ b )—SO 2 —, R″b being H or a (C 1 -C 6 )alkyl group, —CO—NH—, and —NH—CO—, for use for the treatment of pathologies characterized by bronchoconstriction, such as asthma.

Claims (16)

1. A method for treating a pathology characterized by bronchoconstriction, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound having the following formula (VI):

wherein:

p is an integer from 1 to 3 inclusive,

X′ is chosen from the group consisting of: —S—, —NH—, —NR d —, —CH 2 —, —SO 2 —, and —SO—, R d being H or a (C 1 -C 6 )alkyl group;

q is 0 or is an integer from 1 to 5 inclusive,

the R 3 groups, identical or different, are chosen from the group consisting of: (C 1 -C 6 )alkyl groups, halogen atoms, (C 1 -C 6 )alxoxy groups, (C 1 -C 6 )thioalkyl groups, and —NR a R b groups, R a and R b , identical or different, being H or a (C 1 -C 6 )alkyl group;

m is 0 or is an integer from 1 to 5 inclusive,

the R 2 groups, identical or different, are chosen from the group consisting of: halogen atoms, (C 1 -C 6 )alkyl groups, (C 1 -C 6 )alkoxy groups, (C 1 -C 6 )thioalkyl groups, —SCF 3 , —SF 5 , and —NR a R b groups, R a and R b , identical or different, being H or a (C 1 -C 6 )alkyl group.

2. The method of claim 1 , wherein the pathology characterized by bronchoconstriction is asthma.

3. The method of claim 1 , wherein the compound has the following formula (VII):

wherein:

R 5 is a (C 1 -C 6 )alkyl group; and

the R 4 groups, identical or different, are chosen from the (C 1 -C 6 )alkyl groups.

4. The method of claim 1 , wherein the compound has the formula (VI) wherein X′ is —S— or —CH 2 —.

5. The method of claim 1 , wherein the compound has the formula (VI) wherein X′ is —S—.

6. The method of claim 1 , wherein the compound has the formula (VI) wherein q is 0 or 1, and the R 3 groups, identical or different, are chosen from the group consisting of: (C 1 -C 6 )alkyl groups, and (C 1 -C 6 )alxoxy groups.

Assignments (2)
MERGER Recorded Sep 7, 2023
From: UNIVERSITE DE NANTES
To: NANTES UNIVERSITE
Reel/Frame 064824/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2020
From: SAUZEAU, VINCENT; LOIRAND, GERVAISE; LEBRETON, JACQUES; TESSIER, ARNAUD; QUEMENIER, AGNES
To: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE DE NANTES; CHU NANTES
Reel/Frame 052348/0889 →